The antibody specifically binds to domain 1 of an extracellular domain of a VE-cadherin peptide and inhibits new junction formation without disrupting existing junctions.
Figure 1 Antibody E4B9 does not exhibit significant effect on paracellular permeability. Antibodies E4B9 and 6D10 do not exert dramatic effect on vascular permeability.
Figure 2 Antibody E4B9 exhibits potent anti-angiogenesis activity in mouse corneal micropocket assay.
Three representative eyes from each experimental group (6 mice/group) are tested. Antibody E4B9 possesses>80% inhibitory activity on corneal neovascularization.
Figure 3 Effects of the anti-ECD1 (extracellular domain) peptides antibodies on paracellular permeability of H5V cells.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-283CQ-S(P) | Anti-Mouse Cdh5 Recombinant Antibody scFv Fragment (E4B9) | ELISA, WB, IF | |
TAB-283CQ-F(E) | Anti-Mouse Cdh5 Recombinant Antibody Fab Fragment (E4B9) | ELISA, WB, IF |
There are currently no Customer reviews or questions for TAB-283CQ. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.